Loss or decrease in expression of human HLA caused by somatic mutations of HLA genes has been reported in various malignancies. However, mutations in the HLA-DR gene have been rarely noted in hematologic malignancies. Here, we report a case of myelodysplastic syndrome (MDS) with a novel point mutation in exon 2 of the HLA-DRB1*04:03 gene pertaining to a silent mutation (c.357A > T[p.Thr=]). When compared before and after anticancer drug treatment and to the results from the full HLA-matching sibling donor, mutation of the HLA-DRB1 gene suggests clonal evolution. In conclusion, we report a new DRB1*04:03 mutation in an MDS patient at diagnosis that results in a synonymous substitution with unknown clinical impact.
- HLA-DR gene
- myelodysplastic syndrome